Skip to Content

Plegridy Approval History

FDA Approved: Yes (First approved August 15, 2014)
Brand name: Plegridy
Generic name: peginterferon beta-1a
Dosage form: Injection
Company: Biogen
Treatment for: Multiple Sclerosis

Plegridy (peginterferon beta-1a) is a pegylated interferon beta indicated for the treatment of patients with relapsing forms of multiple sclerosis.

Development History and FDA Approval Process for Plegridy

DateArticle
Aug 18, 2014Approval FDA Approves Plegridy (peginterferon beta-1a) for the Treatment of Multiple Sclerosis
Jul 19, 2013US and EU Regulatory Authorities Accept Plegridy (peginterferon beta-1a) Marketing Applications for Review
May 21, 2013Biogen Idec Submits Application to FDA for Approval of Plegridy (Peginterferon Beta-1a) in Multiple Sclerosis

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide